#EULAR2022 POS0282 Febuxostat vs allopurinol: CV risk population study ⭐️16% reduction in all-cause mortality among febuxostat users, mostly non-CV death reduction ⭐️CV safety non-inferior to allopurinol @Rheumnow https://t.co/1oDSioQWPT